Kraig Biocraft Laboratories Appoints Kenneth Le as Managing Director of Prodigy Silk
Kraig Biocraft Laboratories (OTCQB: KBLB), a leader in spider silk technology, has appointed Kenneth Le as Managing Director of its wholly-owned subsidiary, Prodigy Silk Ltd. Le, who has been instrumental in the company's Southeast Asian operations, will oversee the expansion of spider silk rearing and production systems.
Under Le's previous leadership, Kraig Labs and Prodigy Silk have evolved from pilot-scale operations to full-scale commercial rearing centers. In his new role, Le will focus on accelerating production, expanding capacity, and strengthening integration with production partners to advance the commercialization of recombinant spider silk technology.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader nella tecnologia della seta di ragno, ha nominato Kenneth Le Managing Director della sua controllata interamente posseduta, Prodigy Silk Ltd. Le, che ha giocato un ruolo chiave nelle operazioni dell鈥檃zienda nel Sud-est asiatico, supervisioner脿 l'espansione degli allevamenti e dei sistemi produttivi della seta di ragno.
Sotto la precedente guida di Le, Kraig Labs e Prodigy Silk sono passate da progetti pilota a centri di allevamento commerciali su vasta scala. Nel suo nuovo incarico, Le si concentrer脿 sull'accelerazione della produzione, sull'aumento della capacit脿 e sul rafforzamento dell'integrazione con i partner produttivi per promuovere la commercializzazione della tecnologia della seta di ragno ricombinante.
Kraig Biocraft Laboratories (OTCQB: KBLB), l铆der en tecnolog铆a de seda de ara帽a, ha nombrado a Kenneth Le como Managing Director de su filial de propiedad total, Prodigy Silk Ltd. Le, que ha sido fundamental en las operaciones de la compa帽铆a en el sudeste asi谩tico, supervisar谩 la expansi贸n de los sistemas de cr铆a y producci贸n de seda de ara帽a.
Bajo la direcci贸n previa de Le, Kraig Labs y Prodigy Silk han pasado de operaciones a escala piloto a centros de cr铆a comerciales a gran escala. En su nuevo puesto, Le se centrar谩 en acelerar la producci贸n, ampliar la capacidad y reforzar la integraci贸n con los socios de producci贸n para avanzar en la comercializaci贸n de la tecnolog铆a de seda de ara帽a recombinante.
Kraig Biocraft Laboratories (OTCQB: KBLB), 瓯半 鞁ろ伂 旮办垹鞚� 靹犽憪 旮办梾鞚� 鞛愴殞靷� Prodigy Silk Ltd.鞚� 毵る媹歆� 霐旊爥韯半 Kenneth Le毳� 鞛勲獏頄堨姷雼堧嫟. 霃欕偍鞎勳嫓鞎� 靷梾鞐愳劀 頃奠嫭 鞐暊鞚� 頃挫槰 Le電� 瓯半 鞁ろ伂 靷湣 氚� 靸濎偘 鞁滌姢韰滌潣 頇曥灔鞚� 齑濌磩頃╇媹雼�.
Le鞚� 鞚挫爠 毽崝鞁� 頃橃棎 Kraig Labs鞕� Prodigy Silk電� 韺岇澕霟� 攴滊 鞖挫榿鞐愳劀 雽�攴滊 靸侅梾鞝� 靷湣 靹柬劙搿� 氚滌爠頄堨姷雼堧嫟. 靸� 歆侅眳鞐愳劀 Le電� 靸濎偘 臧�靻嶍檾, 靹る箘 頇曥订, 靸濎偘 韺岉姼雱堨檧鞚� 韱淀暕 臧曧檾毳� 韱淀暣 鞛“頃� 瓯半 鞁ろ伂 旮办垹鞚� 靸侅毄頇旊ゼ 於旍頃橂姅 雿� 欤茧牓頃� 鞓堨爼鞛呺媹雼�.
Kraig Biocraft Laboratories (OTCQB: KBLB), leader dans la technologie de la soie d'araign茅e, a nomm茅 Kenneth Le Managing Director de sa filiale 脿 100 %, Prodigy Silk Ltd. Le, qui a jou茅 un r么le d茅terminant dans les op茅rations de la soci茅t茅 en Asie du Sud-Est, supervisera l'expansion des syst猫mes d'茅levage et de production de soie d'araign茅e.
Sous la direction pr茅c茅dente de Le, Kraig Labs et Prodigy Silk sont pass茅s d'op茅rations 脿 l'茅chelle pilote 脿 des centres d'茅levage commerciaux 脿 grande 茅chelle. Dans ses nouvelles fonctions, Le se concentrera sur l'acc茅l茅ration de la production, l'augmentation des capacit茅s et le renforcement de l'int茅gration avec les partenaires de production afin de faire progresser la commercialisation de la technologie de soie d'araign茅e recombinante.
Kraig Biocraft Laboratories (OTCQB: KBLB), ein f眉hrendes Unternehmen im Bereich Spinnenseide-Technologie, hat Kenneth Le zum Managing Director seiner hundertprozentigen Tochtergesellschaft Prodigy Silk Ltd. ernannt. Le, der ma脽geblich an den Aktivit盲ten des Unternehmens in S眉dostasien beteiligt war, wird die Ausweitung der Zucht- und Produktionssysteme f眉r Spinnenseide leiten.
Unter Les bisheriger F眉hrung haben sich Kraig Labs und Prodigy Silk von Pilotprojekten zu kommerziellen Zuchtzentren in gro脽em Ma脽stab entwickelt. In seiner neuen Rolle wird Le sich darauf konzentrieren, die Produktion zu beschleunigen, die Kapazit盲ten zu erweitern und die Integration mit Produktionspartnern zu st盲rken, um die Kommerzialisierung der rekombinanten Spinnenseidentechnologie voranzutreiben.
- Appointment of experienced leader with proven track record in spider silk production
- Successfully scaled from pilot to full-scale commercial operations
- Strong operational expertise in Southeast Asian markets
- No specific production metrics or financial data provided
- Still in development phase for commercial viability
ANN ARBOR, Mich., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a world leader in spider silk technology*, is happy to announce the appointment of Mr. Kenneth Le as Managing Director of its wholly owned recombinant spider silk production subsidiary, Prodigy Silk Ltd.
Le has been an integral leader in the Company鈥檚 Southeast Asian operations for many years, overseeing the expansion of its specialized spider silk rearing and production systems. Under his guidance, Kraig Labs and Prodigy Silk have grown from pilot-scale operations to full-scale commercial rearing centers that continue to set records for spider silk production.
Le brings extensive management experience, operational oversight, and team development expertise. His leadership has been instrumental in creating the foundation for Prodigy Silk鈥檚 current production successes, ensuring that the Company's advanced biotechnology is translated into reliable and sustainable silk output.
"Ken has been at the center of our growth story in Southeast Asia. His ability to combine operational expertise with a deep understanding of our recombinant spider silk technology makes him the ideal choice to lead Prodigy Silk," said Kim Thompson, Founder and CEO of Kraig Labs. "With Ken at the helm, we expect Prodigy Silk to accelerate production, expand capacity, and deliver on the tremendous promise of our technology."
As Managing Director, Le will continue to strengthen Prodigy Silk's production capabilities, optimize rearing operations, strengthen our integration with production partners, and drive forward the Company's mission of bringing recombinant spider silk to global markets.
"I am honored to take on this new role and to continue building on the successes we've achieved," said Le. "We have an extraordinary team, a proven technology, and the momentum to make spider silk a scalable and commercially viable super material. I look forward to leading Prodigy Silk into this next phase of growth."
Kraig Labs' believes Le's leadership will continue to accelerate the pace of innovation and production, positioning Prodigy Silk as the cornerstone of its commercial spider silk operations in Southeast Asia.
For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit .
For details about other recent Kraig Labs advancements, please watch the Company's investor conference at or on the Company's YouTube Channel .
To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go聽to 听听
* For a description of our historical leadership in this technology, please follow this link
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are "forward-looking statements." These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as "believes," "plans," "expects," "anticipates," "foresees," "estimated," "hopes," "if," "develops," "researching," "research," "pilot," "potential," "could" or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, Inc.
(720) 288-8495
Photos accompanying this announcement are available at
FAQ
Who is Kenneth Le and what is his new role at Kraig Biocraft Laboratories (KBLB)?
What are Kenneth Le's responsibilities as Managing Director of KBLB's Prodigy Silk?
How has Prodigy Silk's production capacity evolved under Kenneth Le's leadership?
What is Kraig Biocraft Laboratories' (KBLB) main business focus?
Where are KBLB's main production operations located?
